Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded. During this telephone conference ...

Analysts' ratings for Genmab (NASDAQ:GMAB) over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...

TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...

Genmab A/S (NASDAQ:GMAB – Free Report) – Research analysts at William Blair raised their FY2024 earnings per share (EPS) estimates for shares of Genmab A/S in a note issued to investors on ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Now on Slide 7. As of September 30, our partners had 33 active clinical programs and approved products. During the quarter ...